To date, a few biomarkers have been studied to predict the risk of HT after r-tPA treatment, including blood levels of circulating proteins, such as matrix metalloproteinases, cellular fibronectin, or vascular adhesion protein-1 [2,12–15]. This evidence concerns the gene PLAT and hematocrit.